Document is current
Any future updates will be listed below
-
Authors
Liu, Shaofeng
Zheng, Chunxing https://orcid.org/0000-0002-8668-0873
Nechanitzky, Robert
Luo, Ping
Ramachandran, Parameswaran
Nguyen, Dat
Elia, Andrew J.
Moghadas Jafari, Soode
Law, Rhoda
Snow, Bryan E.
Wakeham, Andrew C.
Berger, Thorsten
Chen, Hui
Gill, Kyle T.
Mcwilliam, Ryan
Fortin, Jerome
Modares, Nastaran Fazel
Saunders, Mary E.
Murakami, Kiichi
Qiu, Yangmin https://orcid.org/0000-0001-6039-7909
You, Zhiwei
Mohtashami, Mahmood https://orcid.org/0000-0001-7952-1869
Qi, Hai https://orcid.org/0000-0001-5475-3989
Ohashi, Pamela S.
Zúñiga-Pflücker, Juan Carlos https://orcid.org/0000-0003-2538-3178
Mak, Tak W. https://orcid.org/0000-0001-6766-861X
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research
Cancer Research Institute
- License Information
-
More Information
Article History
Received: 19 March 2024
Accepted: 4 April 2025
First Online: 21 May 2025
Competing interests
: T.W.M. holds equity in Treadwell Therapeutics Inc. and is a consultant for AstraZeneca Inc. H.Q. is a cofounder of Emergent Biomed Solutions, Ltd. P.S.O. is a Scientific Advisory Board member for Providence Therapeutics, Tikva Allocell and Rondo Therapeutics, Inc. P.S.O. also holds a sponsored research agreement with Providence Therapeutics. The other authors declare no competing interests.
